CClinicalTrials.gg
Active, not recruitingNCT07528469Updated Sep 28, 2026

The Effects of PeptiStrong and Whey on Muscle Function In Older Adults

An interventional study of PeptiStrong + whey protein and Whey protein in Healthy Ageing, Protein Supplementation and Muscle Health, sponsored by Nuritas Ltd. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 60 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Nuritas Ltd · Not applicable, Interventional, and Other

Updated Sep 28, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Non-randomized
Ages
60 Years to 85 Years
Sex
All
01

Study summary

Examining the effects of PeptiStrong and protein on muscle function in older adults

Read the detailed description

The aim of this study is to compare two protein drinks containing whey protein (derived from milk) in healthy adults aged 60 to 85 years. One group will consume a standard whey protein drink (20g), while the other group will consume a drink with half the total protein dose (10g) made of whey protein and PeptiStrong, a fava bean hydrolysate containing bioactive peptides.

The study will assess whether the lower protein drink containing PeptiStrong will lead to equal or greater improvements than the standard drink in physical function, such as the ability to stand up from a chair, walk at a normal pace, maintain balance, and grip strength. The study will also examine markers related to inflammation, fatigue, and quality of life.

The intended value of this research is to improve understanding of how targeted nutritional strategies may help maintain or improve muscle function in older adults. The findings may help inform future nutritional recommendations and the development of practical dietary interventions aimed at supporting healthy ageing and independence.

02

Conditions studied

  • Healthy Ageing
  • Protein Supplementation
  • Muscle Health
  • Muscle Function
  • Hand Grip Strength
  • Longevity
  • Peptides

Keywords

  • Healthy Aging
  • Protein supplementation
  • Muscle function
  • Physical performance
  • Longevity
  • Bioactive peptides
  • Hand grip strength
  • Short performance physical battery
  • Nuritas
  • Liverpool John Moore University
03

In context

Lead sponsor

Nuritas Ltd is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Men and women aged 60 to 85 years at the time of enrolment
  • Community-dwelling (living independently or with minimal assistance)
  • Able to walk independently (with or without a walking aid) and complete simple physical function tests (such as standing up from a chair and walking short distances)
  • Willing and able to attend two study visits at the research facility (baseline and end of study)
  • Willing and able to consume a protein drink containing whey protein (derived from milk) once daily for 30 days
  • Able to understand the study information and provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Any known food allergy or intolerance to fava bean protein or milk protein
  • Diagnosed kidney disease or any medical condition where increased protein intake is contraindicated
  • Yes to any of the answers on the "Older Adult Functional Assessment Screening Questionnaire"
  • Individuals with implanted electronic devices
  • Current or recent (within the past 3 months) participation in another clinical research study involving a nutritional or exercise intervention
  • Conditions that significantly impair mobility or balance such that safe completion of the physical function tests is not possible
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    PeptiStrong + whey protein

    2.4g PeptiStrong (provides 1.6g protein) + 8.4g of whey protein = 10g total protein

    Dietary Supplement: PeptiStrong + whey protein

  • Active comparator
    Whey protein

    20g whey protein

    Dietary Supplement: Whey protein

Interventions

  • Dietary supplementPeptiStrong + whey protein

    Fava bean protein hydrolysate containing bioactive peptides mixed with whey protein as dry powder for drinkable protein shake

  • Dietary supplementWhey protein

    Whey protein as dry powder for drinkable protein shake

06

What researchers measure

Primary outcomes

  1. Hand Grip Strength via hand held dynamometer

    Change from baseline to end of study in grip strength as assessed via hand held dynamometer

    Time frame: Baseline to Week 4

Secondary outcomes

  1. Chair Stand Test - Part of short performance physical battery

    Change from baseline to end of study in physical function assessment via chair stands. This test measures the time taken to complete 5 sit-to-stand repetitions in seconds. A lower time (fewer seconds) = better performance. As part of the full short performance physical battery it is converted to a subscore of 0-4, where a higher score = better performance

    Time frame: Baseline to week 4

  2. Gait Speed as part of short performance physical battery

    Change from baseline to end of study in physical function assessment assessed as time to walk a fixed distance in seconds and reporting in meters per second. Higher speeds indicate better performance. This is converted to a subscore of 0-4 within the full short performance physical battery

    Time frame: Baseline to week 4

  3. 6 Minute Walking Endurance Test

    Change from baseline to end of study in physical function and endurance assessed as the total distance walked in 6 minutes in meters. A greater distance reflects better walking endurance and functional capacity.

    Time frame: Baseline to week 4

  4. Balance test as part of short performance physical battery

    Change from baseline to end of study in balance as assessed by the ability to hold three standing positions of increasing difficulty: side-by-side, semi-tandem, and tandem stance in seconds. Higher scores indicate better balance. The overall score is converted to a a sub-score of 0-4 within the full short performance physical battery.

    Time frame: Baseline to week 4

  5. Balance assessment via force plates

    Change from baseline to end of study in balance as assessed via force plates

    Time frame: Baseline to week 4

  6. Quality of Life via the Sarcopenia Quality of Life (SarQoL®) Questionnaire

    Change from baseline to end of study in quality of life as measured via subjective SarQOL questionnaire. The total score ranges from 0 to 100, with higher scores reflecting a higher quality of life.

    Time frame: Baseline to week 4

  7. Fatigue via Multidimensional Fatigue Inventory Questionnaire

    Change from baseline to end of study in self-reported fatigue as assessed via multidimensional fatigue inventory questionnaire. This 20-item questionnaire covers five dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation, and Reduced Activity. Each subscale score ranges from 4 to 20, with higher scores indicating greater fatigue

    Time frame: Baseline to week 4

  8. C-reactive protein (CRP) via blood test

    Change from baseline to the end of study in inflammatory marker C-reactive protein (CRP) in serum as mg/L

    Time frame: Baseline to week 4

  9. Interleukins via blood test

    Change from baseline to the end of study in Interleukin inflammatory markers in serum as pg/mL

    Time frame: Baseline to week 4

  10. Body composition: Muscle mass and body fat via bioelectrical impedance analysis

    Change from baseline to end of study in muscle mass and body fat as measured by bioelectrical impedance analysis in kilograms and % of total body weight

    Time frame: Baseline to week 4

07

Study locations

1 site
  • LJMU, Byrom Street
    Liverpool, L3 3AF, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Recruiting→Active, not recruiting
changed Sep 28, 2026
Enrollment
80 (estimated)→81 (actual)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Recruiting→Active, not recruiting
    Enrollment 80 (estimated)→81 (actual)
    + 5 other changes: verification date, date precision, design details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07528469
Lead sponsor
Nuritas Ltd
Collaborators
Liverpool John Moores University
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
Apr 6, 2026
Primary completion
Jul 30, 2026
Completion
Oct 30, 2026 (estimated)
Last update
Sep 28, 2026

Study contacts

Graeme Close, Professor
principal investigator · Liverpool John Moore University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion